Regenerative biotechnology
CTM Capilar + D
Mesenchymal stem cells with dutasteride for adjuvant treatment of androgenic alopecia.
Subdermal solution of native mesenchymal stem cells combined with dutasteride, aimed at modulating inflammation, stimulating follicular regeneration, and reducing hair follicle miniaturization.
Composition
Native mesenchymal stem cells and dutasteride.
Pharmaceutical form
Solution
Monovette with 4 ml.
Plastic monovette with 4 ml.
Therapeutic Properties
Promotes hair follicle repair through immunomodulation, secretion of growth factors, collagen stimulation, increased cellular proliferation, inhibition of apoptosis, and reduction of dihydrotestosterone through 5a-reductase blockade.
- Stimulation of follicular regeneration.
- Reduction of scalp inflammation.
- Inhibition of follicular miniaturization.
- Reduction of local dihydrotestosterone.
- Increase in cellular proliferation.
- Inhibition of follicular apoptosis.
- Local immunological modulation.
- Support for hair recovery.
Mechanism of action & Clinical data
The CTMs migrate to the hair follicle, secrete regenerative factors and immunomodulate; dutasteride inhibits type 1 and 2 5a-reductase, reducing DHT.
Indications
Adjuvant in the treatment of androgenic alopecia.
Administration
Subdermal application with 30 G x 13 mm needle; 0.2 ml per point, spaced 1 cm apart.
Contraindications
Sensitivity to formula components. Diagnosis of neoplasia. Pregnancy and breastfeeding.
Storage
Store refrigerated between 2 and 5 C, protected from direct sunlight. Do not freeze.
